Retatrutide
Retatrutide is an investigational medication that activates three hormone receptors (GIP, GLP-1, and glucagon) at the same time. Phase 2 trials showed up to 24% body weight loss at 48 weeks, and it is currently in Phase 3 development.
Verified sources for Retatrutide
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Retatrutide
Triple receptor agonist that activates GIP, GLP-1, and glucagon receptors, producing synergistic effects on appetite, metabolism, and energy expenditure.
GLP-1 receptor activation suppresses appetite and delays gastric emptying, an established satiety pathway.
GIP receptor activation may complement satiety effects (proposed), contributing to enhanced weight loss.
Glucagon receptor activation increases hepatic energy expenditure and fatty acid oxidation, a unique addition contributing to enhanced weight loss.
Triple mechanism produces weight loss exceeding dual GIP/GLP-1 agonists, as Phase 2 trials showed up to 24.2% weight loss at highest dose.
GLP-1 activation enhances glucose-dependent insulin release, improving glycemic control.
Improvements in HbA1c, liver fat, blood pressure, and lipid profiles observed in trials, with broad metabolic benefits
Read Full Retatrutide Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss
Are Oral Peptides Here? Inside the Breakthrough and What's Next
Oral semaglutide just proved cardiovascular benefit, Eli Lilly cleared Phase 3, and a microneedle pill raised a billion dollars. Where the oral peptide era actually stands, and what it means for research peptides.
UPDATE: Retatrutide Clears First Phase 3 Diabetes Trial — 16.8% Weight Loss, 2.0% A1C Drop
Eli Lilly’s triple-agonist retatrutide delivered superior A1C and weight reductions in its first Phase 3 diabetes trial. Full TRANSCEND-T2D-1 breakdown.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
Retatrutide Phase 3 Results: 28.7% Weight Loss and Beyond
Eli Lilly's triple-agonist retatrutide delivered record-breaking weight loss in the TRIUMPH-4 trial. Here's what the Phase 3 data means for the future of obesity treatment.